GV, Orient Life and Illumina Ventures are in line to exit cell therapy and vaccine developer SQZ Biotechnologies, which has filed for a $75m offering.
SQZ Biotechnologies, a US-based cell therapy developer backed by corporates Alphabet, Orient Life and Illumina, has filed to raise up to $75m in its initial public offering.
Founded in 2013, SQZ is working on cell therapy treatments for cancer and infectious diseases based on research at Massachusetts Institute of Technology. Part of the IPO proceeds will go to completing an ongoing phase 1 clinical trial for a cancer vaccine candidate known as SQZ-PBMC-HPV.
Additional cash has been earmarked for progression…
